Patents Assigned to ULTUPHARMA AB
-
Patent number: 11981755Abstract: The present invention relates to novel compounds, which presents a peptide structure and an unexpected antibacterial effect even against certain multiresistant bacteria. The compounds may be cyclic peptides, sometimes depsipeptides, or non-ring-closed peptides, as defined by Formula (I). Further, the invention relates to the medical use of the herein claimed compounds, a method for the production of the compounds as well as a method of treatment including the compounds. In addition, the invention relates to a pharmaceutical preparation comprising one or more of the herein described and claimed compounds combined with suitable carrier(s) and/or adjuvant(s). Finally, the invention is the use of one or more of the claimed compounds in a method for decolonization of a surface of Gram-positive and/or Gram-negative bacteria.Type: GrantFiled: August 27, 2019Date of Patent: May 14, 2024Assignee: ULTUPHARMA ABInventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
-
Publication number: 20210269483Abstract: The present invention relates to novel compounds, which presents a peptide structure and an unexpected antibacterial effect even against certain multiresistant bacteria. The compounds may becyclic peptides, sometimes depsipeptides, ornon-ring-closed peptides, asdefined by Formula (I). Further, the invention relates to the medical use of the herein claimed compounds, a method for the production of the compounds as well as a method of treatment including the compounds. In addition, the invention relates to a pharmaceutical preparation comprising one or more of the herein described and claimed compounds combined with suitable carrier(s) and/or adjuvant(s). Finally, the invention is the use of one or more of the claimed compounds in a method for decolonization of a surface of Gram-positive and/or Gram-negative bacteria.Type: ApplicationFiled: August 27, 2019Publication date: September 2, 2021Applicant: ULTUPHARMA ABInventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD
-
Patent number: 10933048Abstract: The invention relates to compounds of Formula I, wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula I in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.Type: GrantFiled: October 2, 2019Date of Patent: March 2, 2021Assignee: Ultupharma ABInventors: Anders Broberg, Pierre Andersson, Jolanta Levenfors, Joakim Bjerketorp, Christer Sahlberg
-
Patent number: 10828317Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.Type: GrantFiled: May 24, 2018Date of Patent: November 10, 2020Assignee: Ultupharma ABInventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
-
Patent number: 10828316Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.Type: GrantFiled: January 27, 2017Date of Patent: November 10, 2020Assignee: ULTUPHARMA ABInventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
-
Publication number: 20200138777Abstract: The invention relates to compounds of Formula I, wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula I in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.Type: ApplicationFiled: October 2, 2019Publication date: May 7, 2020Applicant: ULTUPHARMA ABInventors: Anders BROBERG, Pierre ANDERSSON, Jolanta LEVENFORS, Joakim BJERKETORP, Christer SAHLBERG
-
Patent number: 10471043Abstract: The invention relates to compounds of Formula (I), wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula (I) in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.Type: GrantFiled: December 2, 2016Date of Patent: November 12, 2019Assignee: Ultupharma ABInventors: Anders Broberg, Pierre Andersson, Jolanta Levenfors, Joakim Bjerketorp, Christer Sahlberg
-
Publication number: 20180360802Abstract: The invention relates to compounds of Formula (I), wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula (I) in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.Type: ApplicationFiled: December 2, 2016Publication date: December 20, 2018Applicant: ULTUPHARMA ABInventors: Anders BROBERG, Pierre ANDERSSON, Jolanta LEVENFORS, Joakim BJERKETORP, Christer SAHLBERG
-
Publication number: 20180325934Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.Type: ApplicationFiled: January 27, 2017Publication date: November 15, 2018Applicant: ULTUPHARMA ABInventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD
-
Publication number: 20180280417Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.Type: ApplicationFiled: May 24, 2018Publication date: October 4, 2018Applicant: ULTUPHARMA ABInventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD